Abstracts of 5 young student researchers will be chosen for the Young Participants Award. The name of the young authors must appear first in the author list and the abstract should be specified as a candidate for the award. Winners will have free registration and 5 mins to present their abstracts at the end of the specific session.
The following hotels have reduced rates for ICQA delegates from 11.05.2022 to 15.05.2022. When booking please specify the promotion code.
Dorint Hotel Hamburg-Eppendorf
Martinistrasse 72, 20251 Hamburg
134€/night single room
164€/night double room
30.03.22 remaining unreserved
rooms go on sale to the public
1. A special issue on CoQ10 in health has been opened in Antioxidants. All authors that submit a paper will have a 15% discount as regular ICQA members. Expected publication in 2021. To update your membership please contact Monica Glebocki at firstname.lastname@example.org
Deadline for manuscript submissions: 31 December 2020.
2. A special issue has been approved in Free Radical in Biology & Medicine edited by Alberto Sanz and Plácido Navas that appears in the journal web. Topic: Mitochondrial Coenzyme Q Homeostasis: signaling, respiratory chain stability and diseases. Expected publication in 2021.
To apply please send a CV including a statement of research interests and names of 2 references to: Catarina M Quinzii (email@example.com), by February 29, 2020. Selected applicants will be invited to an interview in person or via Skype. Candidates will be informed about the selection by March 2020 with a projected June 2020 start date. The selected candidate must submit the necessary documents to Columbia University. Foreign applicants are encouraged to apply early to ensure adequate time to obtain visas
Alberto Sanz, PhD
Principal Research Associate
Institute for Cell and Molecular Biosciences &
Newcastle University Institute for Ageing
Campus for Ageing and Vitality
Newcastle upon Tyne
United Kingdome-mail: firstname.lastname@example.org
Tel: +44191 208 1221
Seville/Madrid, 2nd November 2016. The European Medicines Agency (EMA) has designated Ubiquinol as an orphan drug for the treatment of primary coenzyme Q10 deficiency, a serious rare disease which produces muscular, nervous system and kidney disorders and can cause failures of other organs.